Edwards Lifesciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Edwards Lifesciences (EW).

Price Target Range — 9 Quarters

Analyst Consensus — 20 Analysts

17Buy

3Hold

Consensus RatingBuy# Analysts20Avg. Consensus PT$100Upside to Avg. PT+8.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 7, 2026	Barclays	Christopher Pasquale	Initiate	Overweight	$110
Sep 11, 2026	BTIG	Marie Thibault	Maintained	Buy	$110
Jul 28, 2026	UBS	Patrick Wood	Assumes	Neutral→Buy	$110
Jul 24, 2026	Leerink Partners	Mike Kratky	Upgrade	Market Perform→Outperform	$87→$101
Jul 24, 2026	JP Morgan	Robbie Marcus	PT Raise	Overweight	$100→$105
Jul 24, 2026	Piper Sandler	Adam Maeder	PT Raise	Overweight	$100→$101
Jul 16, 2026	Truist Securities	Richard Newitter	PT Raise	Hold	$90→$95
Jul 15, 2026	Mizuho	Anthony Petrone	PT Raise	Outperform	$100→$105
Jul 13, 2026	RBC Capital	Shagun Singh	PT Raise	Outperform	$100→$110
Jul 8, 2026	Citigroup	Joanne Wuensch	PT Raise	Buy	$101→$110
Jul 6, 2026	Evercore ISI Group	Vijay Kumar	PT Raise	Outperform	$93→$100
Jun 30, 2026	BTIG	Marie Thibault	PT Raise	Buy	$100→$110
Jun 16, 2026	RBC Capital	Shagun Singh	Maintained	Outperform	$100
Jun 2, 2026	TD Cowen	Joshua Jennings	PT Raise	Buy	$97→$104
Apr 27, 2026	Barclays	Matt Miksic	PT Raise	Overweight	$104→$110
Apr 24, 2026	Evercore ISI Group	Vijay Kumar	PT Raise	Outperform	$92→$93
Apr 24, 2026	Truist Securities	Richard Newitter	PT Raise	Hold	$89→$90
Apr 24, 2026	Canaccord Genuity	William Plovanic	PT Cut	Hold	$87→$85
Apr 24, 2026	BTIG	Marie Thibault	PT Raise	Buy	$98→$100
Apr 24, 2026	Baird	David Rescott	PT Raise	Neutral	$85→$87

Analyst Ratings News

PRO
Barclays Initiates Coverage On Edwards Lifesciences with Overweight Rating, Announces Price Target of $110

Barclays analyst Christopher Pasquale initiates coverage on Edwards Lifesciences (NYSE:EW) with a Overweight rating and announces Price Target of $110.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Edwards Lifesciences, Maintains $110 Price Target

BTIG analyst Marie Thibault reiterates Edwards Lifesciences (NYSE:EW) with a Buy and maintains $110 price target.

Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on Edwards Lifesciences, Raises Price Target to $105

JP Morgan analyst Robbie Marcus maintains Edwards Lifesciences (NYSE:EW) with a Overweight and raises the price target from $100 to $105.

Benzinga Newsdesk

PRO
Piper Sandler Reiterates Overweight on Edwards Lifesciences, Raises Price Target to $101

Piper Sandler analyst Adam Maeder reiterates Edwards Lifesciences (NYSE:EW) with a Overweight and raises the price target from $100 to $101.

Benzinga Newsdesk

Edwards Earnings Add Fuel To Bullish MedTech Thesis, Analyst Says

Edwards Lifesciences tops Q2 Wall Street estimates with $1.74B in revenue. EW stock jumps as analysts see continued upside ahead.

Vandana Singh

PRO
Truist Securities Maintains Hold on Edwards Lifesciences, Raises Price Target to $95

Truist Securities analyst Richard Newitter maintains Edwards Lifesciences (NYSE:EW) with a Hold and raises the price target from $90 to $95.

Benzinga Newsdesk

Edwards Lifesciences Corp

ニュース

パートナーシップ

ベンジンガ・グローバル

Edwards Lifesciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Barclays Initiates Coverage On Edwards Lifesciences with Overweight Rating, Announces Price Target of $110

PRO
BTIG Reiterates Buy on Edwards Lifesciences, Maintains $110 Price Target

PRO
JP Morgan Maintains Overweight on Edwards Lifesciences, Raises Price Target to $105

PRO
Piper Sandler Reiterates Overweight on Edwards Lifesciences, Raises Price Target to $101

Edwards Earnings Add Fuel To Bullish MedTech Thesis, Analyst Says

PRO
Truist Securities Maintains Hold on Edwards Lifesciences, Raises Price Target to $95

People Also Watch

People Also Watch

Edwards Lifesciences Corp

ニュース

パートナーシップ

ベンジンガ・グローバル

Edwards Lifesciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROBarclays Initiates Coverage On Edwards Lifesciences with Overweight Rating, Announces Price Target of $110

PROBTIG Reiterates Buy on Edwards Lifesciences, Maintains $110 Price Target

PROJP Morgan Maintains Overweight on Edwards Lifesciences, Raises Price Target to $105

PROPiper Sandler Reiterates Overweight on Edwards Lifesciences, Raises Price Target to $101

Edwards Earnings Add Fuel To Bullish MedTech Thesis, Analyst Says

PROTruist Securities Maintains Hold on Edwards Lifesciences, Raises Price Target to $95

People Also Watch

People Also Watch

PRO
Barclays Initiates Coverage On Edwards Lifesciences with Overweight Rating, Announces Price Target of $110

PRO
BTIG Reiterates Buy on Edwards Lifesciences, Maintains $110 Price Target

PRO
JP Morgan Maintains Overweight on Edwards Lifesciences, Raises Price Target to $105

PRO
Piper Sandler Reiterates Overweight on Edwards Lifesciences, Raises Price Target to $101

PRO
Truist Securities Maintains Hold on Edwards Lifesciences, Raises Price Target to $95